RxDoctor Payments Data

Ronald Dalman, MD

Vascular Surgery · Palo Alto, CANPI 1639253834

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,250 of the $5,179 with a category attached, or 62.7%. Kowa Research Institute, Inc. accounts for 62.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $2,649 and has fallen 93.4% since, to $176 in 2025.

$5,179in general payments, 2019–2025

Across 26 payments — averaging $199.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Research Institute, Inc.$3K
  • Medtronic$713
  • W. L. Gore & Associates, Inc.$524
  • Johnson & Johnson$341
  • Silk Road Medical, Inc.$190
  • Boston Scientific$137
  • plus $24 from 1 others
$330,853in research payments, 2019–2025

Across 103 payments — averaging $3212.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$331K

What the payments were for

  • Consulting fees$3,25063%
  • Grants$240%
  • Travel & lodging$140%
  • Food & beverage$1,89137%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,179 in reported general payments places this provider in the 55th percentile of 519 vascular surgery providers in California.

See all vascular surgery providers in California

Medicare billing

Part B allowed, 2024
$44,378
Medicare patients
171
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other vascular surgery in Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →